Navigation Links
SironRX Therapeutics Raises $3.4 Million Series A
Date:8/16/2011

CLEVELAND, Aug. 16, 2011 /PRNewswire/ -- SironRX Therapeutics, a biotechnology company developing novel regenerative therapies to accelerate dermal and bone healing, announced today a $3.4 million Series A investment led by North Coast Angel Fund.  Additional investors include Cleveland Clinic, JumpStart Inc., Fletcher Spaght Investments, Glengary LLC, Ohio Tech Angel Fund III, Early Stage Partners, X Gen Ltd. and a significant number of individuals.  

(Logo: http://photos.prnewswire.com/prnh/20110816/DC52317LOGO)

"We are excited to have secured this financing from a strong investor syndicate that includes both venture capitalists and angel investors," states Rahul Aras, Ph.D., who is SironRX's co-founder, President and CEO. "We will use the funds to build the SironRX team and execute on key clinical-stage milestones."

SironRX has exclusively licensed JVS-100 in the fields of dermal and bone repair from Juventas Therapeutics.  JVS-100 encodes Stromal cell-Derived Factor 1 (SDF-1), a naturally occurring factor that activates the body's own repair processes.  Juventas is developing JVS-100 for treatment of cardiovascular disease and recently completed a successful Phase I clinical trial demonstrating safety and preliminary efficacy in Class III heart failure patients.

"While the SDF-1 repair biology is well-conserved in nearly all end-organ systems, including the heart, skin and bone, the final product formulations, delivery and target clinical indications will differ significantly between the two companies," indicates Marc Penn, M.D., Ph.D., SironRX's Co-Founder and Chief Scientific Officer and Director of Research for the Summa Cardiovascular Institute.  "Separating the companies allows each to develop SDF-1 for very different market segments in a focused and orderly way."

SironRX will undertake its initial clinical trials to evaluate
'/>"/>

SOURCE SironRX Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Novel Flavonoid Compounds That Significantly Reduce Cancer Cell Growth Are Available For Further Research and Development as Anti-Cancer Therapeutics
2. United Therapeutics Corporation Reports Second Quarter 2011 Financial Results
3. Peloton Therapeutics Completes $18 Million Series A Financing
4. United Therapeutics Corporation To Announce Second Quarter 2011 Financial Results Before Market Open on Thursday, July 28, 2011
5. Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment
6. Oxygen Healthcare (O2h) Announces Expanded Chemistry Collaboration With Heptares Therapeutics
7. Dr. Andrew Scharenberg, M.D., to Serve as Chief Scientific Officer for Cellectis therapeutics
8. Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
11. Sorrento Therapeutics Innovative Approach to Developing Vaccines and Therapeutics for MRSA Receives Continued Support From the National Institute of Allergy and Infectious Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 The American ... of original research, reviews and editorials addressing developments ... practice, today published a provocative article exploring the ... progression and potential treatment of prostate cancer. ... and proposes the possibility that there could be ...
(Date:12/19/2014)... OR and Hershey, PA (PRWEB) December 19, 2014 ... Pink: BJCT), a leading developer and manufacturer of ... entered into an agreement with Immunomic Therapeutics, Inc. ... Biojector®-2000 needle-free injection device with its LAMP™ vaccine ... an option for an exclusive Worldwide license to ...
(Date:12/19/2014)... , Dec. 19, 2014 Naurex Inc., ... novel drugs for diseases of the central nervous system, ... and chief executive officer, will present at the 33 ... presentation will take place at 3:00 p.m. PST on ... in San Francisco, Calif. ...
(Date:12/19/2014)... Dec. 19, 2014 Decision Resources Group finds ... at a 12 percent compound annual growth rate through ... aging population and the increasing adoption of dental implants. ... will also spur demand for dental biomaterials because ... and periodontal treatments. Other key findings from ...
Breaking Biology Technology:Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3
... , PRINCETON, N.J., Aug. 14 DOR ... late-stage biopharmaceutical company, today announced its financial results for the second ... which primarily relate to receipts from National Institutes of Health (NIH) ... compared to $0.5 million for the second quarter of 2008. ...
... NEW YORK, Aug. 14 /PRNewswire-Asia-FirstCall/ -- Tiens Biotech ... ), http://www.tiens-bio.com ,today announced financial results for the second ... Revenue for the second quarter of 2009 increased 4.6% to ... reflecting an,increase in sales in China. , ...
... , , CLEVELAND, Aug. ... and services company focused on global eClinical solutions for the ... operating results for the second quarter and first-half of 2009 ... report as filed with Pink OTC Markets will be available ...
Cached Biology Technology:DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments 2DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments 3DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments 4DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments 5Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 2Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 3Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 4Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 5Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 6Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 7Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 8Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 9Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 10Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 11Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 12DATATRAK International, Inc. to Release 2009 Second Quarter and First-Half Operating Results on August 17, 2009 2DATATRAK International, Inc. to Release 2009 Second Quarter and First-Half Operating Results on August 17, 2009 3DATATRAK International, Inc. to Release 2009 Second Quarter and First-Half Operating Results on August 17, 2009 4
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
(Date:12/10/2014)...  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ... in long-term mass consumer adoption of wearable products," said ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... Howard Hughes Medical Institute (HHMI) scientists has peeled back some ... off genes selectively to control critical events of development. The ... the structure of Dicer, an enzyme that enables cells to ... in the January 13, 2005, issue of the journal Science ...
... Biobank, a visionary medical project aimed at improving the ... and many other serious conditions is launched this week ... three thousand people living in the south Manchester area ... before it goes nationwide later this year. , They ...
... at the University of Minnesota Medical School have discovered a ... have properties of primitive stem cells. , Umbilical ... that can only produce cells found in blood. The ... cells with the characteristics of more primitive stem cells that ...
Cached Biology News:Molecule does more than slice and dice RNA 2Molecule does more than slice and dice RNA 3Molecule does more than slice and dice RNA 4Multi-million pound UK Biobank underway 2Multi-million pound UK Biobank underway 3
... gradient system is ideal for routine binary separations. ... sensitive Adept CE 4201 UV-Visible variable wavelength detector. ... provided by the two highly accurate and ... 4100 solvent delivery pumps., Chromatograms may be plotted ...
...
... cells were cultured in RPMI 1640 medium with ... phase of growth. In order to keep ... fixed in acetone-methanol. The cells are arrayed ... with each wells surface specifically treated to enhance ...
... cultured in RPMI 1640 with 2 mM L-glutamine ... In order to keep the antigens in ... The cells are arrayed on a 12-well ... surface specifically treated to enhance cellular attachment and ...
Biology Products: